G. Waldron

Reducing safety-related drug attrition: the use of in vitro pharmacological profiling

Gareth J Waldron, S. Whitebread, J. Hamon, 2012, Nature Reviews Drug Discovery.

Zebrafish assays as early safety pharmacology screens: paradigm shift or red herring?

Rob Wallis, Jean-Pierre Valentin, Matthew J Winter, 2008, Journal of pharmacological and toxicological methods.

Recommendations for safety pharmacology evaluations of oligonucleotide-based therapeutics.

Gareth J Waldron, D. Kornbrust, K. Cannon, 2014, Nucleic acid therapeutics.

The discovery of a potent Nav1.3 inhibitor with good oral pharmacokinetics.

J. Warmus, P. Cox, C. Markworth, 2017, MedChemComm.

The Discovery of a Potent, Selective, and Peripherally Restricted Pan-Trk Inhibitor (PF-06273340) for the Treatment of Pain.

Kiyoyuki Omoto, Angus Nedderman, Sharan K Bagal, 2016, Journal of medicinal chemistry.

Zebrafish based assays for the assessment of cardiac, visual and gut function--potential safety screens for early drug discovery.

Gareth J Waldron, Angeleen Fleming, Iain Gardner, 2008, Journal of pharmacological and toxicological methods.

Discovery of Potent, Selective, and Peripherally Restricted Pan-Trk Kinase Inhibitors for the Treatment of Pain.

Gareth J Waldron, R. Grimley, M. Andrews, 2018, Journal of medicinal chemistry.

Patch clamping by numbers.

Christine Williams, Claire Wood, Gareth J Waldron, 2004, Drug discovery today.

A Role for the Middle C Terminus of G-protein-activated Inward Rectifier Potassium Channels in Regulating Gating*

Gareth J Waldron, G. Waldron, Yuan Guo, 2002, The Journal of Biological Chemistry.

Discovery of Allosteric, Potent, Subtype Selective, and Peripherally Restricted TrkA Kinase Inhibitors.

R. Grimley, J. Bilsland, J. Cui, 2019, Journal of medicinal chemistry.